

Anti-TIGIT / DIA-TG1 / BSA free Mouse monoclonal anti-T cell marker (Immune checkpoint protein) Clone TG1

Product Information

Catalog No.:	DIA-TG1-SB-02 - 200µg DIA-TG1-SB-05 - 500µg antibody lyophilizate w/o BSA	Reconstitution:	DIA-TG1-SB-02, restore to 200 µl DIA-TG1-SB-05, restore to 500 µl Reconstitute w. PBS pH 7.4, 0.05% NaN ₃ , Leave liquid 15min on antibody film/pellet, redissolve antibody by vortexing.
Clone:	TG1	Presentation:	In PBS pH 7.4, 0.05% NaN ₃ , Antibody purified from culture supernatant
Concentration:	1mg/ml	Applications:	Immunohistochemistry (IHC), (standard formalin-fixed paraffin sections)
Isotype:	Mouse IgG1/k	Dilutions:	1:200 IHC-P (General recommendation, validation of anti- body performance/protocol is the responsibility of the end user. Positive/negative controls should be run simultaneously with patient specimen. Interpretation must be made by a qualified pathologist within the context of pa- tient's clinical history/other diagnostic tests.)
Specificity:	TIGIT	Associated Antibodies:	DIA-TG2-M, anti-TIGIT, clone TG2 DIA-R12, anti-PVRIG/CD112R, clone R12
Immunogen:	Recombinant peptide from extracellular domain of human TIGIT		
Physical State:	Lyophilized powder		
Species			
Reactivity:	Human		
Positive Control:	Tonsil		
Visualization:	Membranous		

Reactivity

Clone TG1 is the first monoclonal antibody detecting TIGIT in routine formalin-fixed paraffin-embedded tissue specimen. It has been validated for the identification of TIGIT positive T-cells infiltrating human tumors in order to allow the detection of TIGIT in the tumor microenvironment under pathological conditions.

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a member of the poliovirus receptor (PVR) family and acts as an immune checkpoint protein expressed on subsets of T lymphocytes. The expression of TIGIT has been reported on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells, but it is not expressed on B cells or naive CD4+ T cells. TIGIT may be upregulated on naive CD4+ T cells upon activation. TIGIT has been shown to be upregulated on T cells in multiple cancer models. The ligands CD155 and CD112 are also highly expressed on dendritic cells and macrophages in several types of cancer. Additionally, TIGIT expression is highly correlated with the expression of other coinhibitory molecules, including PD-1. In addition to directly inhibiting cytotoxic T-cell activity, TIGIT can foster an immunosuppressive microenvironment through its impact on other immune cells, for example, by binding to CD155 on the surface of dendritic cells or by manipulating NK cell activity. TIGIT inhibiting drugs are currently being developed. Immunohistochemical application of monoclonal antibody TG1 may provide valuable information for clinical research and potential therapeutic interventions specifically targeting the TIGIT-related tumor immunology checkpoint.

Instructions for Use

Immunohistochemical staining of standard formalin-fixed paraffin sections

Deparaffinize and rehydrate according to standard procedures. Heat induced epitope retrieval (HIER) is required. Stringent heat pretreatment in an autoclave at 121°C (5min) is recommended (Tris-EDTA-citrate, pH 7.8, e.g. TEC-buffer). An automated straining protocol has been established on Leica Bond RX exclusively (see our Tech.Note at www.oncodianova.com), protocols for other automated stainers have not been established. For biotin/(strept)avidin-based detection techniques (e.g. Vectastain® Elite® ABC-HRP-kit/AEC) use the antibody at 1:50 dilution. For a polymer-based detection technique (e.g. Dako EnVision™ detection system, Peroxidase/DAB) use the antibody at 1:100-150 dilution. The antibody stains cell membranes of various lymphocyte subtypes. Weak non-specific nuclear/nucleolar staining may occur in some epithelial tissues (i.e. colon cancer).

Storage and Stability

Store the lyophilized antibody at 2-8°C. For long term storage freeze at -20°C, thus the antibody is stable for at least one year. As reconstituted liquid store at 2-8°C short term (several weeks). Avoid repeated freeze / thaw cycles.

Safety Notes


The material contains 0.05% sodium azide as preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material. Avoid skin and eye contact, inhalation and ingestion.



Figures

Immunohistochemistry of human TG1 in routine formalin-fixed paraffin-embedded tissue samples

- A:** Normal human tonsil with numerous TIGIT-positive lymphocytes
B: Tumor infiltrating lymphocytes in colorectal carcinoma
C: Inflammatory lymphoid infiltrate in Hashimoto thyroiditis
D: Sarcoid granuloma interspersed with TIGIT-positive lymphocytes



References for clone TG1

1. Niebel D et al. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. *Clinical Epigenetics* 14:50 doi.org/10.1186/s13148-022-01270-2 (2022)
2. Murakami et al. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. *PLoS One* 2022 Mar 24;17(3):e0265908. doi: 10.1371/journal.pone.0265908 (2022)
3. Annibali, O., Bianchi, A., Grifoni, A. et al. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma. *Sci Rep* 11, 7059. doi: 10.1038/s41598-021-86655-8 (2021)
4. Scimeca, M. et al. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. *Urol. Oncol.* 37, 297.e19-297.e31. doi: 10.1016/j.urolonc.2019.02.013 (2019).
5. Hinsch A et al. et al. Expression of the immune checkpoint receptor TIGIT in seminoma. *Oncol Lett.*, 18: 1497–1502. doi: 10.3892/ol.2019.10428 (2019).
6. Blessin NC et al. Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer. *Disease Markers*, Volume 2019, Jan 10. Article ID 5160565. doi.org/10.1155/2019/5160565 (2019).
7. Li W et al. Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. *BMC Cancer*, 18: 1209, doi.org/10.1186/s12885-018-5111-1 (2018).

For research use only. Not for diagnostic or therapeutic use.

Changes of the original product formulation or composition for commercial use are expressly prohibited.

